Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Segment Information - Additional Information (Details)

v3.22.4
Segment Information - Additional Information (Details)
€ in Thousands
 12 Months Ended
Dec. 31, 2022
EUR (€)
Customer
Segment
Dec. 31, 2021
EUR (€)
Customer
Dec. 31, 2020
EUR (€)
Customer
Disclosure of operating segments [line items]      
Number of segments | Segment 2    
Number of external customers exceeds10% group's revenue | Customer 0 0 0
Percentage of revenue increased 16.60% 27.50%  
Increase in revenue from contract with customer € 139,760 € 181,883  
Total assets 1,659,698 1,418,842  
Total liabilities € 663,788 577,183  
Unallocated Amounts      
Disclosure of operating segments [line items]      
Total assets   279,342 € 2,396
Total liabilities   € 77,603 € 217,890
Reportable Segments      
Disclosure of operating segments [line items]      
Number of segments | Segment 2    
Biopharmaceutical and Diagnostic Solutions      
Disclosure of operating segments [line items]      
Segment sales percentage 81.00% 82.00%  
Percentage of operating profit margin 22.80% 21.40% 18.10%
Percentage of gross profit margin 34.30% 33.10% 29.60%
Biopharmaceutical and Diagnostic Solutions | Operating Segments      
Disclosure of operating segments [line items]      
Percentage of revenue increased 15.30% 22.80%  
Increase in revenue from contract with customer € 26,961    
Increase decrease in revenue 106,065 € 129,145  
Total assets 1,259,124 885,733  
Total liabilities € 511,022 € 335,919  
Engineering      
Disclosure of operating segments [line items]      
Segment sales percentage 19.00% 18.00%  
Percentage of operating profit margin   10.50% 10.80%
Percentage of gross profit margin   19.30% 20.90%
Engineering | Operating Segments      
Disclosure of operating segments [line items]      
Percentage of revenue increased 36.80% 42.60%  
Increase decrease in revenue € 80,639 € 65,428  
Total assets 370,851 253,767  
Total liabilities € 256,835 € 163,661  
Bottom of Range | Drug Containment Systems      
Disclosure of operating segments [line items]      
Segment sales percentage 50.00%